🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Denmark / NCT06503510
Recruiting Not applicable

Role of Interleukin-13 Pathways on Pain and Itch Sensitivity

NCT06503510 · tracked via the Priya Life Science Denmark tracker
Phase
Not applicable
Started
2025-01-06
Last updated
2025-06-04

Condition(s) studied

Itch

Investigational drug(s) / intervention(s)

HistamineCowhagebovine adrenal medulla (BAM8-22)

Histamine: A small drop of histamine dihydrochloride (1%, in saline) will be applied to a previously determined area on the volar forearm followed by a prick through the drop.

Cowhage: Approximately 30-35 cowhage spicules will be manually inserted into the subject's skin.

bovine adrenal medulla (BAM8-22): A small drop of BAM8-22 solution will be applied to a previously determined area on the volar forearm followed by a prick through the drop.

Study summary

Atopic dermatitis (AD) is as chronic, inflammatory skin disorder affecting 20% of the world's population. Intense itch and skin pain are the main symptoms. Research has shown that the proteins interleukins are involved in inflammation and itch in atopic dermatitis. The medicinal product called Lebrikizumab, used for treatment of AD, has shown to block the interleukin called IL-13. The purpose of this experiment is to evaluate the role of IL-13 in itch in both healthy subjects and people with atopic dermatitis.

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Healthy men and women * 18-60 years Exclusion Criteria: * Pregnancy or lactation * Drug addiction defined as any use of cannabis, opioids, or other drugs * Previous or current history of neurological, dermatological (e.g., AD, psoriasis, etc.), immunological, musculoskeletal, cardiac disorder, or psychiatric diagnoses that may affect the results (e.g., neuropathy, muscular pain in the upper extremities, anxiety, depression, schizophrenia, etc.) * Moles, wounds, scars, or tattoos in the area to be treated or tested * Current use of medications that may affect the trial such as antihistamines and pain killers (use of antihistamines should be discontinued 72 hours before the experiment and all topical agents and emollients should be discontinued 24 hours before the experiment). * Use of systemic and topical corticosteroids * Consumption of alcohol or painkillers 24 hours before the study days and between these * Acute or chronic pain * Participation in other trials within one week of study entry (four weeks in the case of pharmaceutical trials) * Lack of ability to cooperate

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
Aalborg University Gistrup Aalborg Recruiting
CNAP Gistrup Aalborg Active Not Recruiting
Aalborg University Aalborg Denmark Not Yet Recruiting

More Aalborg University trials in Denmark

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06503510 on ClinicalTrials.gov ↗ ← All trials in Denmark